Carol Berry
Director/Board Member at Venn Biosciences Corp.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Martin LeBlanc | M | 58 |
CellCarta Biosciences, Inc.
 CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | 24 years |
| Jenny Rooke | M | - |
Venn Biosciences Corp.
 Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | - |
| Klaus N. Lindpaintner | M | 69 |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | - |
| Pascale Witz | F | 57 |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | - |
| Mark Kockx | M | - |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | - |
| Jim Rothman | M | - |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | - |
| Joshua Stahl | M | 38 |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | 1 years |
| David Michael | M | - |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | 4 years |
| Dirk Hendriks | M | - |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | - |
| Jason W. Myers | M | 48 |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | 2 years |
| Stephana Patton | M | 54 |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | - |
| Ryan Bethencourt | M | - |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | 7 years |
| David Spaight | M | 65 |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | - |
| Stephen McLean | M | 66 |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | - |
| Eugene Gorbach | M | 47 |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | - |
| William Castell | M | 76 |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | - |
| James Zou | M | - |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Erwin Estigarribia | M | - |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | 4 years |
| Aldo Carrascoso | M | - |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA. | 6 years |
| Gail Page | M | 68 | 8 years | |
| William C. Wallen | M | 81 | 7 years | |
| Jim Burns | M | 77 | 15 years | |
| Simon C. Shorter | M | 63 | 5 years | |
| Fahmy Ziad Fahmy Saifi | M | - |
University of Dallas
| 2 years |
| Chris Duff | M | - |
University of Dallas
| 4 years |
| Rujing Tang | M | - |
University of Dallas
| 2 years |
| Yoichiro Kamitani | M | 45 |
University of Dallas
| 2 years |
| Debra A. Young | F | 58 | 1 years | |
| William C. Sullivan | M | - | 3 years | |
| James P. Merryweather | M | - | 2 years | |
| Stephen T. Lundy | M | 62 | 1 years | |
| Chris Terry | M | 56 |
University of Dallas
| 4 years |
| Wendell Wierenga | M | 76 | 3 years | |
| Matt Hogan | M | 64 | 6 years | |
| William E. Rich | M | - | 11 years | |
| Rajen K. Dalal | M | 70 | 6 years | |
| Judy Bruner | F | 65 | 5 years | |
| Kenneth J. Conway | M | 75 | 3 years | |
| Egisto Boschetti | M | - | 5 years | |
| Jordan Clancy | M | - |
University of Dallas
| - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 31 | 77.50% |
| Canada | 9 | 22.50% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Carol Berry
- Personal Network
